Broadening the use of antiretroviral therapy: the case for feline leukemia virus

Willie M Greggs III^1,3, Christine L Clouser^1,2, Steven E Patterson^1,4, Louis M Mansky^1,2,3,4,5
1Institute for Molecular Virology, ²Department of Diagnostic and Biological Sciences, School of Dentistry, ³Comparative Molecular Biosciences Program, College of Veterinary Medicine, ⁴Center for Drug Design, Academic Health Center, ⁵Department of Microbiology, Medical School, University of Minnesota, MN, USA

Abstract: Antiretroviral drugs have saved and extended the lives of millions of individuals infected with HIV. The major classes of anti-HIV drugs include reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry/fusion inhibitors. While antiretroviral drug regimens are not commonly used to treat other types of retroviral infections, there are instances where there is a perceived need for re-evaluation of the benefits of antiretroviral therapy. One case in point is that of feline leukemia virus (FeLV), an infection of companion felines. While vaccines exist to prevent FeLV infection and spread, they have not eliminated FeLV infection. For FeLV-infected felines and their human companions, antiretroviral therapy would be desirable and of practical importance if good options were available. Here, we discuss FeLV biology and current treatment options, and propose that there is a need for antiretroviral treatment options for FeLV infection. The comparative use and analysis of antiretroviral therapy can provide new insights into the mechanism of antiretroviral drug action.

Keywords: felid, cancer, antiviral, gammaretrovirus, lymphocyte, veterinary